ロード中...
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study
Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our cen...
保存先:
| 出版年: | Leuk Lymphoma |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5521009/ https://ncbi.nlm.nih.gov/pubmed/27494751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1217528 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|